- Home
- HTGC vs NAMS Comparison
HTGC vs NAMS Comparison
Compare HTGC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTGC | NAMS |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | HTGC | NAMS |
|---|---|---|
| Price | $16.60 | $34.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $21.00 | ★ $47.38 |
| AVG Volume (30 Days) | ★ 1.9M | 610.4K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | ★ 11.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $516,847,000.00 | $35,243,000.00 |
| Revenue This Year | $10.13 | N/A |
| Revenue Next Year | $9.62 | $11.19 |
| P/E Ratio | $9.58 | ★ N/A |
| Revenue Growth | 4.54 | ★ 4.91 |
| 52 Week Low | $15.65 | $14.06 |
| 52 Week High | $22.04 | $42.00 |
Technical Indicators
Market Signals| Indicator | HTGC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 56.91 |
| Support Level | $16.22 | $33.14 |
| Resistance Level | $17.00 | $35.61 |
| Average True Range (ATR) | 0.38 | 1.46 |
| MACD | -0.16 | 0.42 |
| Stochastic Oscillator | 15.12 | 88.42 |
Price Performance
Historical ComparisonAbout HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.